Anti-IL-33 Antibody Dosing for COPD Exacerbation Reduction

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for COPD, including maximal triple therapy, are insufficient in reducing moderate to severe exacerbations, leading to a substantial unmet medical need.

Innovation Solution

Administration of anti-IL-33 antibodies or antibody variants, specifically dosed between 150 mg to 600 mg at intervals of every 4 to 8 weeks, to inhibit IL-33 activity in the lung, thereby disrupting the inflammatory structural damage cycle in COPD patients.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If maximal triple therapy (LABA+LAMA+ICS) is used, then maintenance treatment is provided, but moderate to severe exacerbations continue to occur in 30-40% of patients

Engineering Contradiction:

Improveeffectiveness of maintenance therapyVSAvoidfrequency of exacerbations

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces anti-IL-33 antibody as an intermediary substance that mediates between the existing maintenance therapy and the harmful exacerbations. The antibody binds to IL-33 cytokine, blocking its pro-inflammatory effects and disrupting the exacerbation cycle without interfering with the existing LABA+LAMA+ICS therapy mechanism.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the biological parameter by targeting IL-33 cytokine levels in the lung. By administering anti-IL-33 antibody, the concentration of active IL-33 is reduced, which fundamentally alters the inflammatory profile and reduces exacerbation frequency beyond what conventional maintenance therapy can achieve.

Inventive Principle:

Principle #35Parameter changes

2Productivity

If conventional maintenance inhaled therapy is optimized, then treatment is improved, but a substantial unmet medical need remains for reducing exacerbations

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidexacerbation reduction

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent extracts the specific harmful mechanism (IL-33 cytokine signaling) from the complex COPD pathology. By isolating and targeting IL-33 specifically with the anti-IL-33 antibody, the treatment addresses the specific driver of exacerbations rather than providing non-specific maintenance therapy.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent segments the maintenance therapy into two components: conventional inhaled therapy (LABA+LAMA+ICS) for general maintenance, and anti-IL-33 antibody for specific exacerbation prevention. This segmentation allows each component to optimize its specific function without interfering with the other.

Inventive Principle:

Principle #1Segmentation

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Achieves therapeutic benefits by reducing IL-33 activity, potentially leading to decreased exacerbations, improved lung function, and enhanced health-related quality of life for COPD patients.

Implementation Method 1

Neutralisation of IL-33 activity with MEDI3506 has potential to disrupt the cycle of inflammatory structural damage in lungs of patients with COPD

Methodology Applied

Scientific EffectAntibody-cytokine binding:

Data Source

PatentUS20250136676A1Treatment Of Chronic Obstructive Pulmonary Disease With An Anti-Interleukin-33 Antibody

Publication Date: 2025.05.01 MEDIMMUNE LTD

AI summary

The present disclosure relates to methods of treating COPD, particularly by administering an anti-IL-33 antibody or antibody variant thereof in a specified dosing regimen.